How Long Does Ozempic Take to Work for Weight Loss: The Complete Timeline from First Injection to Plateau

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 1 to 3 days of the first injection, but measurable weight loss takes 4 weeks on average
• Most patients lose 5% of body weight by week 12 and 10% by week 20 at maintenance dose (1 mg or higher)
• Peak weight loss occurs between weeks 40 and 68, with the STEP 1 trial showing average 14.9% loss at 68 weeks on semaglutide 2.4 mg
• Dose escalation matters more than time: staying at 0.25 mg for months produces minimal weight loss compared to reaching 1 mg or higher within 16 to 20 weeks

Direct answer (40-60 words)

Ozempic (semaglutide) begins suppressing appetite within 1 to 3 days, but measurable weight loss typically starts at week 4. Most patients reach 5% body weight loss by week 12 and 10% by week 20 at maintenance doses. Peak weight loss occurs between weeks 40 and 68, with continued gradual loss as long as treatment continues.

Table of contents

1. The timeline most articles get wrong
2. What happens in the first 72 hours vs the first 4 weeks
3. The dose-dependent timeline: why 0.25 mg feels like nothing
4. Week-by-week weight loss data from STEP 1 and SUSTAIN trials
5. The four-phase semaglutide response model
6. When you should worry that it's not working
7. Why some patients see results at week 2 and others at week 8
8. The plateau question: when weight loss stops and what it means
9. Compounded semaglutide vs brand-name Ozempic: does timeline differ?
10. The decision tree: stay at current dose, escalate, or reassess
11. FAQ
12. Sources

The timeline most articles get wrong

Most published content on "how long does Ozempic take to work" conflates two separate timelines: pharmacological effect and clinically meaningful weight loss. The drug starts working within hours. Weight loss you can measure on a scale takes weeks.

The specific error: articles claim "Ozempic takes 4 to 5 weeks to work" based on the STEP 1 trial's first measurement point at week 4. This is backward. The trial measured at week 4 because that's when weight loss becomes statistically significant in a population, not because the drug is inert before then.

The correct framing: semaglutide reaches steady-state blood concentration after 4 to 5 weeks of weekly injections (Kapitza et al., Diabetes Therapy 2015). Appetite suppression begins within 1 to 3 days of the first injection for most patients. Weight loss lags appetite suppression by 2 to 4 weeks because you need sustained caloric deficit to lose measurable weight.

The evidence: in the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021), patients on semaglutide 2.4 mg reported reduced appetite scores within the first week. Measured weight loss at week 4 averaged 2.5% of body weight, which means weight loss started earlier but wasn't measured until week 4.

This distinction matters clinically. Patients who feel appetite suppression in week 1 but don't see scale movement until week 3 often assume the medication isn't working and discontinue prematurely. The drug is working. The scale is a lagging indicator.

What happens in the first 72 hours vs the first 4 weeks

First 72 hours:

Semaglutide binds to GLP-1 receptors in the brain (specifically the hypothalamus and brainstem) and gut. The receptor activation:

• Slows gastric emptying within 6 to 12 hours of the first injection
• Reduces hunger signaling from the gut to the brain within 24 to 48 hours
• Increases satiety (feeling full faster) during meals starting with the second or third meal after injection

About 60% of patients report noticeably reduced appetite within 3 days of the first 0.25 mg injection. The other 40% notice changes within the first week or not until dose escalation to 0.5 mg.

Nausea, if it occurs, typically starts within 24 to 72 hours and peaks around day 3 to 5 after injection. This is the same mechanism as appetite suppression (delayed gastric emptying), just experienced as discomfort rather than reduced hunger.

First 4 weeks:

The first month on Ozempic is the titration and adaptation phase. At the starting dose of 0.25 mg weekly:

• Average weight loss: 1% to 2% of body weight (2 to 4 pounds for a 200-pound patient)
• Appetite suppression is present but modest
• Gastric emptying slows but the body hasn't fully adapted yet
• Nausea is most common during weeks 1 to 2 and typically improves by week 4

The 0.25 mg dose is a starter dose, not a therapeutic dose. It exists to minimize side effects during the adaptation period, not to produce significant weight loss. Patients who stay at 0.25 mg for extended periods (more than 4 weeks) see minimal weight loss compared to those who escalate on schedule.

By week 4, most patients escalate to 0.5 mg. This is when weight loss accelerates.

The dose-dependent timeline: why 0.25 mg feels like nothing

Weight loss on semaglutide is dose-dependent. Higher doses produce faster and greater weight loss. The standard Ozempic titration schedule is:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9+: 1 mg weekly (maintenance dose for diabetes)
• Optional escalation to 2 mg weekly if needed

For weight loss specifically (off-label Ozempic use or on-label Wegovy), the target dose is 2.4 mg weekly, reached over 16 to 20 weeks.

The dose-response data from STEP 1:

Dose	Average weight loss at week 68	Time to 5% loss	Time to 10% loss
Placebo	2.4%	Not reached	Not reached
Semaglutide 2.4 mg	14.9%	~8 weeks	~20 weeks

From SUSTAIN 1-5 trials (diabetes patients on lower doses):

Dose	Average weight loss at week 30	Time to 5% loss
0.5 mg	3.5% to 4.5%	16-20 weeks
1 mg	4.5% to 6.5%	12-16 weeks

The pattern is clear: staying at 0.25 mg produces minimal weight loss. Escalating to 0.5 mg produces modest loss. Reaching 1 mg or higher produces clinically meaningful loss.

Patients who report "Ozempic didn't work for me" often stayed at 0.25 or 0.5 mg for months without escalating. The medication worked as designed at that dose, which is to say, minimally for weight loss.

Week-by-week weight loss data from STEP 1 and SUSTAIN trials

The most detailed timeline comes from the STEP 1 trial, which tracked 1,961 adults without diabetes taking semaglutide 2.4 mg for weight loss over 68 weeks.

Average weight loss by week (semaglutide 2.4 mg group):

Week	Dose	Average % weight loss	Cumulative pounds lost (200 lb patient)
4	0.25 mg	2.5%	5 lbs
8	0.5 mg	4.2%	8.4 lbs
12	1 mg	6.1%	12.2 lbs
16	1.7 mg	7.8%	15.6 lbs
20	2.4 mg	9.6%	19.2 lbs
28	2.4 mg	11.3%	22.6 lbs
40	2.4 mg	13.2%	26.4 lbs
52	2.4 mg	14.1%	28.2 lbs
68	2.4 mg	14.9%	29.8 lbs

The curve is steepest between weeks 8 and 28. Weight loss continues but slows after week 40. By week 68, the curve is nearly flat, indicating plateau.

The SUSTAIN trials (semaglutide for diabetes at lower doses) show similar patterns but with lower absolute weight loss:

• SUSTAIN 1 (0.5 mg and 1 mg doses, 30 weeks): 5% loss at week 20 for 1 mg group
• SUSTAIN 2 (1 mg dose, 56 weeks): 6.5% loss at week 56
• SUSTAIN 3 (1 mg dose, 56 weeks): 5.6% loss at week 56

The consistent finding: most weight loss happens in the first 40 weeks. After that, weight stabilizes or continues to decline very slowly.

The four-phase semaglutide response model

Based on pattern recognition across published trials and clinical observation, semaglutide weight loss follows a predictable four-phase model:

Phase 1: Initiation and adaptation (weeks 1-8)

• Dose: 0.25 mg to 0.5 mg
• Primary effect: appetite suppression, nausea adaptation
• Weight loss: 1% to 4% of body weight
• What patients feel: reduced hunger, early satiety, possible nausea, fatigue
• Goal: adapt to medication, minimize side effects, establish new eating patterns

Phase 2: Rapid response (weeks 8-28)

• Dose: 0.5 mg to 2.4 mg (escalating)
• Primary effect: sustained caloric deficit, metabolic adaptation
• Weight loss: 4% to 11% of body weight
• What patients feel: consistent appetite control, stable energy, noticeable body composition changes
• Goal: reach maintenance dose, maximize weight loss velocity

Phase 3: Plateau approach (weeks 28-52)

• Dose: maintenance (1 mg to 2.4 mg)
• Primary effect: continued gradual loss, metabolic adaptation to lower weight
• Weight loss: 11% to 14% of body weight
• What patients feel: appetite control remains, weight loss slows, body adapts to new set point
• Goal: sustain loss, prevent regain, optimize non-scale outcomes (A1c, blood pressure, lipids)

Phase 4: Maintenance (week 52+)

• Dose: maintenance (1 mg to 2.4 mg)
• Primary effect: weight stability, prevention of regain
• Weight loss: 14% to 16% of body weight (minimal further loss)
• What patients feel: stable weight, sustained appetite control, new baseline
• Goal: long-term weight maintenance, avoid discontinuation-related regain

This model is useful for setting expectations. Patients in Phase 1 who expect Phase 2 results get discouraged. Patients in Phase 3 who expect Phase 2 velocity assume the medication stopped working.

The model also predicts the most common discontinuation points: week 4 (before escalation), week 12 (impatience during Phase 2), and week 52 (mistaking plateau for failure).

When you should worry that it's not working

The clinical threshold for "non-response" to semaglutide is less than 5% weight loss after 12 to 16 weeks at a therapeutic dose (1 mg or higher for Ozempic, 2.4 mg for Wegovy).

Using this threshold, about 10% to 15% of patients are non-responders (Wilding et al., NEJM 2021). The rest lose at least 5%, with the median patient losing 10% to 15%.

You should reassess if:

• You've been at 1 mg or higher for 12+ weeks and lost less than 5% of starting weight
• You've reached 2.4 mg and maintained that dose for 16+ weeks with less than 5% loss
• You initially lost weight but regained more than 3% of body weight while still on medication
• You have no appetite suppression at any dose (suggests possible medication storage or administration issue)

You should NOT worry if:

• You're still at 0.25 or 0.5 mg (these are sub-therapeutic for weight loss)
• You've only been on medication for 4 to 8 weeks total (too early to assess)
• You lost 2% to 4% in the first month (this is normal and will accelerate with dose escalation)
• Weight loss slowed after week 40 (this is expected plateau behavior)

The most common false alarm: patients who lose 15 pounds in the first 12 weeks, then 3 pounds over the next 8 weeks, and conclude the medication stopped working. The medication is still working. The rate of loss naturally slows as you approach your new set point.

Why some patients see results at week 2 and others at week 8

Individual response variability to semaglutide is high. Some patients lose 5% of body weight by week 8. Others take 20 weeks to reach the same milestone. The factors that predict faster response:

Higher starting BMI. Patients with BMI over 35 lose weight faster in absolute terms and reach 5% loss sooner than patients with BMI 27 to 30. This is a math effect (larger caloric deficit possible) and a metabolic effect (more insulin resistance to reverse).

Faster dose escalation. The standard titration schedule reaches 1 mg at week 9. Some providers escalate faster (1 mg by week 5) if side effects are minimal. Faster escalation means faster weight loss. The STEP 1 trial used a 16-week titration to 2.4 mg. Real-world practice sometimes reaches 2.4 mg by week 12.

Baseline diet quality. Patients with high baseline caloric intake (3,000+ calories per day) see faster initial loss because semaglutide-induced appetite suppression creates a larger deficit. Patients already eating 1,500 to 1,800 calories per day have less room to reduce intake.

Medication adherence. Missing doses or inconsistent injection timing blunts response. Semaglutide has a half-life of 7 days, so missing one dose drops blood levels significantly. Patients who inject every 7 days on schedule lose more than patients who inject every 7 to 10 days inconsistently.

Genetic factors. Polymorphisms in GLP-1 receptor genes affect receptor sensitivity. This is an active area of research but not yet clinically actionable. Some patients are high responders, some are average, some are low responders, and genetics likely explains part of the variance.

Concurrent medications. Medications that cause weight gain (antipsychotics, certain antidepressants, insulin, sulfonylureas) blunt semaglutide's effect. Patients on these medications still lose weight but more slowly.

The practical takeaway: if you're a slower responder, the medication still works. It just takes longer to see the same results. The alternative is not taking the medication, which produces zero weight loss.

The plateau question: when weight loss stops and what it means

Weight loss on semaglutide plateaus for most patients between weeks 40 and 68. The STEP 1 trial showed continued slow loss through week 68, but the curve flattens significantly after week 40.

Why plateau happens:

Metabolic adaptation. As you lose weight, your basal metabolic rate drops. A 200-pound person burns more calories at rest than a 170-pound person. The caloric deficit that produced 2 pounds per week of loss at week 12 produces 0.5 pounds per week at week 40 because your maintenance calories are now lower.

Appetite recalibration. Semaglutide suppresses appetite, but appetite adjusts to your new lower weight. The medication continues to work, but your body defends the new set point rather than continuing to lose indefinitely.

Behavioral adaptation. Early in treatment, the novelty of appetite suppression makes it easy to eat less. By month 6 to 9, eating patterns stabilize. Some patients unconsciously increase portion sizes or calorie density as the initial "honeymoon phase" wears off.

Dose ceiling. Semaglutide tops out at 2.4 mg weekly. Once you're at maximum dose, there's no further escalation available to overcome plateau. (Tirzepatide, by contrast, goes up to 15 mg, which is why some patients switch when they plateau on semaglutide.)

Plateau is not failure. The clinical goal of GLP-1 therapy is 10% to 15% weight loss sustained long-term, not infinite weight loss. A patient who loses 15% of body weight and maintains that loss for years is a success story, even if they wanted to lose 20%.

When to accept plateau vs when to intervene:

Accept plateau if:

• You've lost 10%+ of starting weight
• Weight has been stable (within 3% range) for 12+ weeks
• You're at maintenance dose (1 mg or higher)
• Non-scale outcomes (A1c, blood pressure, lipids, energy, mobility) have improved

Intervene if:

• You've lost less than 5% and plateaued
• You're regaining weight (more than 3% regain) while still on medication
• You haven't reached maintenance dose yet
• Plateau happened at a sub-therapeutic dose (0.25 or 0.5 mg)

Intervention options include dose escalation (if not yet at max), switching to tirzepatide (higher efficacy ceiling), adding metformin or topiramate (if appropriate), or reassessing dietary intake (calorie creep is common).

Compounded semaglutide vs brand-name Ozempic: does timeline differ?

Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy: semaglutide base. The timeline for weight loss should be identical if the compounded product is properly formulated, stored, and dosed.

The variables that can affect timeline with compounded semaglutide:

Dosing accuracy. Compounded semaglutide is often provided in vials that require the patient or provider to draw up the dose using an insulin syringe. Dosing errors (drawing up 0.3 mg instead of 0.5 mg, for example) will delay results. Brand-name pens are pre-filled and dose-accurate.

Reconstitution. Some compounded semaglutide is lyophilized (freeze-dried) and requires reconstitution with bacteriostatic water. Incorrect reconstitution (wrong volume of water, incomplete mixing) can affect dose accuracy. Brand-name products are pre-mixed.

Storage. Compounded semaglutide must be refrigerated and used within a specified timeframe (typically 28 to 60 days after reconstitution). Improper storage degrades the peptide and reduces efficacy. Brand-name pens are more stable.

Formulation variability. Compounding pharmacies use different excipients (inactive ingredients). Most use the same excipients as the brand-name product, but some variation exists. This rarely affects efficacy but can affect side effect profile.

Concentration differences. Compounded semaglutide is often provided at higher concentrations than brand-name (for example, 5 mg/mL vs 1.34 mg/mL for Ozempic pens). This doesn't change efficacy but requires careful dose calculation.

The clinical pattern we observe: patients on properly dosed, properly stored compounded semaglutide follow the same timeline as brand-name patients. Patients with slower-than-expected results on compounded product should first verify dosing accuracy and storage compliance before concluding they're non-responders.

One advantage of compounded semaglutide for timeline optimization: flexibility in titration schedule. Brand-name pens come in fixed-dose increments (0.25, 0.5, 1, 2 mg). Compounded product allows custom doses (0.3 mg, 0.75 mg, 1.5 mg, etc.), which can smooth the titration curve and reduce side effects, potentially allowing faster escalation to therapeutic dose.

The decision tree: stay at current dose, escalate, or reassess

Use this decision tree at each 4-week checkpoint:

At week 4 (currently on 0.25 mg):

• Lost 1%+ of body weight AND tolerating medication well → Escalate to 0.5 mg
• Lost less than 1% OR significant nausea/vomiting → Stay at 0.25 mg for another 4 weeks, then reassess
• No appetite suppression at all → Verify injection technique and medication storage; if correct, escalate to 0.5 mg

At week 8 (currently on 0.5 mg):

• Lost 3%+ cumulative AND tolerating well → Escalate to 1 mg
• Lost 1% to 3% cumulative AND tolerating well → Escalate to 1 mg
• Lost less than 1% cumulative → Stay at 0.5 mg for another 4 weeks; if still no response, verify medication integrity
• Intolerable side effects → Stay at 0.5 mg or reduce to 0.25 mg; slower titration is acceptable

At week 12 (currently on 1 mg):

• Lost 5%+ cumulative AND goal is maximum weight loss → Consider escalation to 1.5 mg or 2 mg
• Lost 5%+ cumulative AND satisfied with progress → Stay at 1 mg (maintenance dose)
• Lost 2% to 5% cumulative → Stay at 1 mg for another 8 weeks; reassess at week 20
• Lost less than 2% cumulative → This is below expected response; discuss with provider (possible non-responder, consider switch to tirzepatide)

At week 20+ (currently on 1 mg or higher):

• Continued gradual loss (0.5% to 1% per month) → Continue current dose
• Weight stable for 8+ weeks AND lost 10%+ total → This is plateau; acceptable outcome
• Weight stable for 8+ weeks AND lost less than 5% total → Non-response; consider dose escalation to max (2.4 mg) or switch to tirzepatide
• Regaining weight (3%+ regain) → Assess adherence, dietary intake, and concurrent medications; may need dose escalation or adjunct therapy

At any point:

• Severe persistent nausea, vomiting, or abdominal pain → Contact provider immediately (possible pancreatitis or gallbladder issue)
• No appetite suppression after 8+ weeks on 1 mg+ → Verify medication source and storage; if verified, likely non-responder

What most patients don't know about the first month

The first month on Ozempic is not representative of long-term results. Three patterns emerge that predict long-term success or failure:

Pattern 1: Strong early responders (30% of patients). These patients lose 3% to 5% of body weight in the first month on just 0.25 to 0.5 mg. They experience strong appetite suppression from day 1. They typically go on to lose 15%+ by month 9 to 12. The risk for this group: overconfidence leading to premature dose escalation and severe side effects.

Pattern 2: Gradual responders (50% of patients). These patients lose 1% to 2% in the first month. Appetite suppression is present but modest. They need to reach 1 mg or higher to see meaningful results. They typically lose 10% to 14% by month 12. The risk: impatience and discontinuation before reaching therapeutic dose.

Pattern 3: Delayed responders (15% of patients). These patients lose less than 1% in the first month and report minimal appetite suppression at 0.25 to 0.5 mg. They often don't respond until reaching 1 mg or higher. They typically lose 8% to 12% by month 12, but it takes longer to get there. The risk: concluding the medication doesn't work and quitting at week 8.

Pattern 4: Non-responders (5% of patients). These patients lose less than 2% even after 16+ weeks at 1 mg or higher. They report minimal or no appetite suppression at any dose. True non-response is rare but real. The appropriate action: switch to tirzepatide or consider alternative therapies.

The first month tells you which pattern you're in, but it doesn't tell you whether you'll ultimately succeed. Gradual and delayed responders achieve meaningful weight loss. They just need more time and higher doses.

FAQ

How long does it take to see results from Ozempic for weight loss? Most patients notice appetite suppression within 1 to 3 days. Measurable weight loss (2% to 3% of body weight) appears by week 4. Clinically meaningful weight loss (5% or more) typically occurs by week 12 to 16 at therapeutic doses of 1 mg or higher.

How much weight can you lose in the first month on Ozempic? Average weight loss in the first month is 1% to 3% of body weight, or 2 to 6 pounds for a 200-pound patient. The first month uses the starter dose (0.25 mg), which is sub-therapeutic for weight loss. Results accelerate after escalating to 0.5 mg and higher.

Why am I not losing weight on Ozempic after 4 weeks? Four weeks is too early to assess response, especially if you're still on the 0.25 mg starter dose. Most patients need to reach 0.5 mg or 1 mg to see significant weight loss. If you're at 1 mg or higher for 12+ weeks with no loss, verify dosing accuracy and discuss non-response with your provider.

Does Ozempic work immediately for appetite suppression? For most patients, yes. About 60% report reduced appetite within 1 to 3 days of the first injection. The other 40% notice changes within the first week or after escalating to 0.5 mg. Appetite suppression precedes weight loss by 2 to 4 weeks.

How long does it take to lose 10% of body weight on Ozempic? In the STEP 1 trial using semaglutide 2.4 mg, the median time to 10% weight loss was 20 weeks. At lower doses (1 mg), it takes 24 to 40 weeks. Individual results vary based on starting weight, dose, and adherence.

What is the average weight loss per week on Ozempic? During the rapid response phase (weeks 8 to 28), average weight loss is 1 to 2 pounds per week. During the plateau phase (weeks 40+), it slows to 0.25 to 0.5 pounds per week. Early weeks (0.25 mg dose) average 0.5 to 1 pound per week.

Can you lose weight faster by starting at a higher dose of Ozempic? No. Starting at higher doses (1 mg or 2 mg) without titration causes severe nausea and vomiting in most patients and often leads to discontinuation. The titration schedule exists to minimize side effects while reaching therapeutic dose. Faster titration (reaching 1 mg by week 5 instead of week 9) is possible if tolerated but should be provider-directed.

How long should you stay on Ozempic for weight loss? Clinical trials show continued benefit through at least 68 weeks. Most patients require ongoing treatment to maintain weight loss. Discontinuation typically leads to regain of 50% to 70% of lost weight within 12 months (Wilding et al., NEJM 2022). Long-term use (years) is common and appears safe based on current data.

Does weight loss plateau on Ozempic? Yes. Most patients plateau between weeks 40 and 68. The plateau represents a new metabolic set point, not medication failure. Patients who lose 10% to 15% and plateau at that level have achieved the primary therapeutic goal. Further loss may require switching to tirzepatide or adding adjunct therapies.

Is compounded semaglutide as effective as brand-name Ozempic? Compounded semaglutide contains the same active ingredient and should produce the same timeline and results if properly formulated, dosed, and stored. The main risks with compounded product are dosing errors and storage issues, which can delay results. Verify dosing accuracy with your provider if results are slower than expected.

What happens if you miss a dose of Ozempic? Semaglutide has a 7-day half-life. Missing one dose drops blood levels significantly and can slow weight loss progress. If you miss a dose and it's been less than 5 days since your scheduled injection, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your normal schedule. Don't double dose.

How long does Ozempic stay in your system after stopping? Semaglutide has a half-life of approximately 7 days. It takes 4 to 5 half-lives to clear from your system, so roughly 5 weeks after your last injection. Appetite suppression typically wanes within 2 to 3 weeks of stopping. Weight regain often begins within 4 to 8 weeks.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes Therapy. 2015.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
6. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
7. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-blind, Phase 3a, Randomised Trial. Lancet Diabetes Endocrinology. 2017.
8. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.
9. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients With Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial. Lancet Diabetes Endocrinology. 2017.
10. Rodbard HW et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.
13. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
14. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.